SCHEMBL4376961

SCHEMBL4376961

N#Cc1ccccc1S(=O)(=O)N1CCC(=NOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.50
▸ GPR183 P32249 1/20 0.48
▸ HTR2A P28223 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.43
▸ ATM Q13315 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TACR1 P25103 2/20 0.38
▸ CTDSP1 Q9GZU7 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ TRPV4 Q9HBA0 1/20 0.38
▸ GBA1 P04062 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377766 0.84 NR3C1 (0.40) PKMKDM4EALDH1A1TDP1L3MBTL1
SCHEMBL4377015 0.83 PKM (0.46) PKMKDM4EALDH1A1GAATSHR
SCHEMBL4379004 0.82 SCN9A (0.44) PKMKDM4EALDH1A1TDP1L3MBTL1
SCHEMBL4380941 0.81 CHRM1 (0.39) PKMALDH1A1L3MBTL1
SCHEMBL4388038 0.81 MAPT (0.47) PKMALDH1A1L3MBTL1GAAMAPT
SCHEMBL4381279 0.80 PKM (0.49) PKMKDM4EALDH1A1L3MBTL1GAA
SCHEMBL4380268 0.80 SCN9A (0.47) PKMNR3C1GAAMAPT
SCHEMBL4385272 0.79 PKM (0.54) PKMHTR2AHTR2CKDM4EALDH1A1
SCHEMBL4378960 0.79 PKM (0.43) PKMHTR2AHTR2CKDM4EALDH1A1
SCHEMBL4379527 0.77 PKM (0.37) PKMALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 PKM 2106/4885GPR183 597/4885HTR2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback